Thioredoxin-1 and its natural inhibitor, vitamin D3 up-regulated protein 1, are differentially regulated by PPARalpha in human macrophages.

Macrophage-derived reactive oxygen species contribute to the initiation and development of atherosclerosis. The cellular balance between oxidative and reductive states depends on the endogenous antioxidant capacity, with the thioredoxin-1 (Trx-1) system playing a major role. Peroxisome proliferator-activated receptor-alpha (PPARalpha) is expressed by human macrophages and exhibits anti-inflammatory properties. Here we show that the selective PPARalpha activator GW647 significantly increased the Trx-1 mRNA and protein expression in human macrophages as determined by quantitative polymerase chain reaction and Western immunoblotting. Consistently, the Trx-1 activity was significantly increased by PPARalpha activation. By contrast, PPARalpha activation led to the down-regulation of vitamin D(3) up-regulated protein 1 (VDUP-1), the physiological inhibitor of Trx-1. Analysis of the Trx-1 and VDUP-1 promoters with gene reporter assays, mutational analysis, gel shift assays and chromatin immunoprecipitation analyses revealed the presence of a functional response element specific for PPARalpha in the Trx-1 promoter and the presence of a functional activator protein 1 (AP-1) site in the VDUP-1 promoter. The interference of PPARalpha/retinoid X receptor alpha with the AP-1 transcription factor elements c-Jun/c-Fos resulted in the inhibition of AP-1 binding and down-regulation of the VDUP-1 gene expression. Finally, PPARalpha activation reduced the lidocaine-induced caspase-3 activity and apoptosis, which might be due to the VDUP-1-mediated regulation of the Bax/Bcl-2 ratio. Together these data indicate that stimulation of PPARalpha in human macrophages might reduce arterial inflammation through differential regulation of the Trx-1 and VDUP-1 gene expression.

[1]  Richard T. Lee,et al.  Vitamin D3–Upregulated Protein-1 (VDUP-1) Regulates Redox-Dependent Vascular Smooth Muscle Cell Proliferation Through Interaction With Thioredoxin , 2002, Circulation research.

[2]  S. Rhee,et al.  Mammalian Peroxiredoxin Isoforms Can Reduce Hydrogen Peroxide Generated in Response to Growth Factors and Tumor Necrosis Factor-α* , 1998, The Journal of Biological Chemistry.

[3]  C. Lowenstein Exogenous thioredoxin reduces inflammation in autoimmune myocarditis. , 2004, Circulation.

[4]  Y. Ishii,et al.  Redox-Sensing Release of Human Thioredoxin from T Lymphocytes with Negative Feedback Loops 1 , 2004, The Journal of Immunology.

[5]  C. Guillemette,et al.  The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor α and γ Target Gene* , 2003, The Journal of Biological Chemistry.

[6]  T. Mazzone,et al.  Transcriptional and post-transcriptional control of apolipoprotein E gene expression in differentiating human monocytes. , 1992, The Journal of biological chemistry.

[7]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[8]  T. Littlewood,et al.  Apoptotic cell death in atherosclerosis , 2003, Current Opinion in Lipidology.

[9]  Kohei Miyazono,et al.  Mammalian thioredoxin is a direct inhibitor of apoptosis signal‐regulating kinase (ASK) 1 , 1998, The EMBO journal.

[10]  P. Ghezzi,et al.  Thioredoxin, a Redox Enzyme Released in Infection and Inflammation, Is a Unique Chemoattractant for Neutrophils, Monocytes, and T Cells , 1999, The Journal of experimental medicine.

[11]  A. Shah,et al.  Peroxisome Proliferator–Activated Receptor &agr; Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL with PPAR-&agr; Activation Properties , 2004 .

[12]  D. Li,et al.  Oxidized Low-Density Lipoprotein Receptor LOX-1 and Apoptosis in Human Atherosclerotic Lesions , 2002, Journal of cardiovascular pharmacology and therapeutics.

[13]  R. Sitia,et al.  Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. , 1992, The Journal of biological chemistry.

[14]  A. Holmgren,et al.  A CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin. , 1995, International immunology.

[15]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  B. Staels,et al.  Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. , 1999, Current opinion in lipidology.

[17]  T. Sawamura,et al.  Oxidized low density lipoprotein potentiation of Fas-induced apoptosis through lectin-like oxidized-low density lipoprotein receptor-1 in human umbilical vascular endothelial cells. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[18]  J. Qu,et al.  Thioredoxin-mediated negative autoregulation of peroxisome proliferator-activated receptor alpha transcriptional activity. , 2006, Molecular biology of the cell.

[19]  G. Powis,et al.  Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. , 2004, Archives of biochemistry and biophysics.

[20]  W. Min,et al.  Thioredoxin Promotes ASK1 Ubiquitination and Degradation to Inhibit ASK1-Mediated Apoptosis in a Redox Activity-Independent Manner , 2002, Circulation research.

[21]  Richard T. Lee,et al.  Hyperglycemia Promotes Oxidative Stress through Inhibition of Thioredoxin Function by Thioredoxin-interacting Protein* , 2004, Journal of Biological Chemistry.

[22]  K. Brand,et al.  Enhanced VDUP‐1 gene expression by PPARγ agonist induces apoptosis in human macrophage , 2008 .

[23]  I. Tabas Consequences and Therapeutic Implications of Macrophage Apoptosis in Atherosclerosis: The Importance of Lesion Stage and Phagocytic Efficiency , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[24]  Jun Ho Jeon,et al.  VDUP1 upregulated by TGF-β1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression , 2003, Oncogene.

[25]  Elias S. J. Arnér,et al.  Physiological functions of thioredoxin and thioredoxin reductase. , 2000, European journal of biochemistry.

[26]  H. DeLuca,et al.  Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. , 1994, Biochimica et biophysica acta.

[27]  K. Umesono,et al.  Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. , 1996, The Journal of clinical investigation.

[28]  Y. Makino,et al.  Direct Association with Thioredoxin Allows Redox Regulation of Glucocorticoid Receptor Function* , 1999, The Journal of Biological Chemistry.

[29]  A. Holmgren,et al.  [21] Thioredoxin and thioredoxin reductase , 1995 .

[30]  Peter Tontonoz,et al.  Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. , 2004, Annual review of cell and developmental biology.

[31]  M. Matsui,et al.  Identification of Thioredoxin-binding Protein-2/Vitamin D3 Up-regulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression* , 1999, The Journal of Biological Chemistry.

[32]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[33]  Wei Chien Huang,et al.  Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel α-methylene-γ-butyrolactone derivatives , 2004 .

[34]  H. Nakamura,et al.  Redox regulation by thioredoxin superfamily; protection against oxidative stress and aging , 2000, Free radical research.

[35]  P. Libby,et al.  Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.

[36]  A. Holmgren,et al.  Thioredoxin and related molecules--from biology to health and disease. , 2007, Antioxidants & redox signaling.

[37]  C. Dive,et al.  Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin , 1994, The Journal of cell biology.

[38]  Frank J. Gonzalez,et al.  Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* , 1999, The Journal of Biological Chemistry.

[39]  K. Ohta,et al.  Lidocaine-induced apoptosis and necrosis in U937 cells depending on its dosage. , 2005, Biomedical research.

[40]  J. Yodoi,et al.  Thiordoxin regulates the DNA binding activity of NF-χB by reduction of a disulphid bond involving cysteine 62 , 1992 .

[41]  D. Rader,et al.  Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an antiinflammatory role for lipoprotein lipase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Elias S. J. Arnér,et al.  Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. , 2001, Free radical biology & medicine.

[43]  H. Um,et al.  Vitamin D3 Up-Regulated Protein 1 Mediates Oxidative Stress Via Suppressing the Thioredoxin Function1 , 2000, The Journal of Immunology.

[44]  K. Schulze-Osthoff,et al.  Thioredoxin as a potent costimulus of cytokine expression. , 1996, Journal of immunology.

[45]  H. Nakamura,et al.  Redox regulation of cellular activation. , 1997, Annual review of immunology.

[46]  S. Noji,et al.  Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. , 1998, Biochemical and biophysical research communications.

[47]  K. Mori,et al.  Distinct Roles of Thioredoxin in the Cytoplasm and in the Nucleus , 1999, The Journal of Biological Chemistry.

[48]  P. Libby,et al.  PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells , 1999 .

[49]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[50]  G. Filomeni,et al.  Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[51]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[52]  B. Staels,et al.  Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* , 1998, The Journal of Biological Chemistry.

[53]  R. Virmani,et al.  Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. , 2000, The American journal of pathology.

[54]  J. Gustafsson,et al.  Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[55]  R. Roberts,et al.  Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. , 1996, Carcinogenesis.

[56]  A. Holmgren,et al.  Thioredoxin and glutaredoxin systems. , 2019, The Journal of biological chemistry.

[57]  D. Templeton,et al.  Regulation of signal transduction through protein cysteine oxidation. , 2006, Antioxidants & redox signaling.

[58]  C. Glass,et al.  Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein , 1998 .

[59]  W. Wahli,et al.  DNA Binding Properties of Peroxisome Proliferator-activated Receptor Subtypes on Various Natural Peroxisome Proliferator Response Elements , 1997, The Journal of Biological Chemistry.

[60]  N. Marx,et al.  Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. , 2004, Circulation research.

[61]  A. Nègre-Salvayre,et al.  Oxidized low-density lipoprotein-induced apoptosis. , 2002, Biochimica et biophysica acta.

[62]  K. Brand,et al.  Extracellular Human Thioredoxin-1 Inhibits Lipopolysaccharide-induced Interleukin-1β Expression in Human Monocyte-derived Macrophages* , 2005, Journal of Biological Chemistry.

[63]  L. Herzenberg,et al.  Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  S. Rhee,et al.  Thioredoxin-dependent peroxide reductase from yeast. , 1994, The Journal of biological chemistry.